Beltra J-C, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR, Chen Z, Casella V, Ngiow SF, Khan O, Huang YJ, Yan P, Nzingha K, Xu W, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Schuchter LM, Huang AC, Wherry EJ (2020) Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity 52:825-841.e8. https://doi.org/10.1016/j.immuni.2020.04.014

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boengler K, Schulz R, Heusch G (2009) Loss of cardioprotection with ageing. Cardiovasc Res 83:247–261. https://doi.org/10.1093/cvr/cvp033

Article  CAS  PubMed  Google Scholar 

Brumberger ZL, Branch ME, Klein MW, Seals A, Shapiro MD, Vasu S (2022) Cardiotoxicity risk factors with immune checkpoint inhibitors. Cardio-Oncology 8:3. https://doi.org/10.1186/s40959-022-00130-5

Article  PubMed  PubMed Central  Google Scholar 

Chen C, Liu X, Chang C-Y, Wang HY, Wang R-F (2023) The interplay between T cells and cancer: the basis of immunotherapy. Genes (Basel). https://doi.org/10.3390/genes14051008

Article  PubMed  PubMed Central  Google Scholar 

Croft M, So T, Duan W, Soroosh P (2009) The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 229:173–191. https://doi.org/10.1111/j.1600-065X.2009.00766.x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Doehner W, von Haehling S, Anker SD (2015) Protective overweight in cardiovascular disease: moving from ‘paradox’ to ‘paradigm.’ Eur Heart J 36:2729–2732. https://doi.org/10.1093/eurheartj/ehv414

Article  PubMed  Google Scholar 

Dolladille C, Akroun J, Morice P-M, Dompmartin A, Ezine E, Sassier M, Da-Silva A, Plane A-F, Legallois D, L’Orphelin J-M, Alexandre J (2021) Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J 42:4964–4977. https://doi.org/10.1093/eurheartj/ehab618

Article  CAS  PubMed  Google Scholar 

Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, Mosarla RC, Lee C, Zlotoff DA, Raghu VK, Hartmann SE, Gilman HK, Gong J, Zubiri L, Sullivan RJ, Reynolds KL, Mayrhofer T, Zhang L, Hoffmann U, Neilan TG (2020) Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation 142:2299–2311. https://doi.org/10.1161/CIRCULATIONAHA.120.049981

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duma N, Abdel-Ghani A, Yadav S, Hoversten KP, Reed CT, Sitek AN, Enninga EAL, Paludo J, Aguilera JV, Leventakos K, Lou Y, Kottschade LA, Dong H, Mansfield AS, Manochakian R, Adjei AA, Dronca RS (2019) Sex Differences in tolerability to anti-programmed cell death protein 1 therapy in patients with metastatic melanoma and non-small cell lung cancer: are we all equal? Oncologist 24:e1148–e1155. https://doi.org/10.1634/theoncologist.2019-0094

Article  CAS  PubMed  PubMed Central  Google Scholar 

Efentakis P, Choustoulaki A, Kwiatkowski G, Varela A, Kostopoulos IV, Tsekenis G, Ntanasis-Stathopoulos I, Georgoulis A, Vorgias CE, Gakiopoulou H, Briasoulis A, Davos CH, Kostomitsopoulos N, Tsitsilonis O, Dimopoulos MA, Terpos E, Chłopicki S, Gavriatopoulou M, Andreadou I (2024) Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin. Basic Res Cardiol. https://doi.org/10.1007/s00395-024-01046-0

Article  PubMed  Google Scholar 

Gergely TG, Brenner GB, Nagy RN, Sayour NV, Makkos A, Kovácsházi C, Tian H, Schulz R, Giricz Z, Görbe A, Ferdinandy P (2023) Effects of bempedoic acid in acute myocardial infarction in rats: no cardioprotection and no hidden cardiotoxicity. Int J Mol Sci. https://doi.org/10.3390/ijms24021585

Article  PubMed  PubMed Central  Google Scholar 

Gergely TG, Drobni ZD, Kallikourdis M, Zhu H, Meijers WC, Neilan TG, Rassaf T, Ferdinandy P, Varga ZV (2024) Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure. Nat Rev Cardiol. https://doi.org/10.1038/s41569-023-00986-9

Article  PubMed  Google Scholar 

Gergely TG, Kucsera D, Tóth VE, Kovács T, Sayour NV, Drobni ZD, Ruppert M, Petrovich B, Ágg B, Onódi Z, Fekete N, Pállinger É, Buzás EI, Yousif LI, Meijers WC, Radovits T, Merkely B, Ferdinandy P, Varga ZV (2023) Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment. Br J Pharmacol 180:740–761. https://doi.org/10.1111/bph.15984

Article  CAS  PubMed  Google Scholar 

Haj-Yehia E, Mincu RI, Korste S, Lampe L, Margraf SM, Michel L, Mahabadi AA, Ferdinandy P, Rassaf T, Totzeck M (2024) High neutrophil-to-lymphocyte ratio is associated with cancer therapy-related cardiovascular toxicity in high-risk cancer patients under immune checkpoint inhibitor therapy. Clin Res Cardiol 113:301–312. https://doi.org/10.1007/s00392-023-02327-9

Article  CAS  PubMed  Google Scholar 

Haslam A, Gill J, Prasad V (2020) Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs. JAMA Netw open 3:e200423. https://doi.org/10.1001/jamanetworkopen.2020.0423

Article  PubMed  PubMed Central  Google Scholar 

Henning RJ (2021) Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity. Am J Cardiovasc Dis 11:504–529

CAS  PubMed  PubMed Central  Google Scholar 

Heusch G (2022) Coronary blood flow in heart failure: cause, consequence and bystander. Basic Res Cardiol 117:1. https://doi.org/10.1007/s00395-022-00909-8

Article  PubMed  PubMed Central  Google Scholar 

Heusch G (2023) Cardioprotection in cardio-oncology: a case for concern? Cardiovasc Res 119:e144–e145. https://doi.org/10.1093/cvr/cvad111

Article  CAS  PubMed  Google Scholar 

Heusch G, Bøtker HE, Ferdinandy P, Schulz R (2023) Primordial non-responsiveness: a neglected obstacle to cardioprotection. Eur Heart J 44:1687–1689. https://doi.org/10.1093/eurheartj/ehad160

Article  PubMed  Google Scholar 

Jing Y, Zhang Y, Wang J, Li K, Chen X, Heng J, Gao Q, Ye Y, Zhang Z, Liu Y, Lou Y, Lin SH, Diao L, Liu H, Chen X, Mills GB, Han L (2021) Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy. J Natl Cancer Inst 113:1396–1404. https://doi.org/10.1093/jnci/djab035

Article  CAS  PubMed  Google Scholar 

Kaboré EG, Guenancia C, Vaz-Luis I, Di Meglio A, Pistilli B, Coutant C, Cottu P, Lesur A, Petit T, Dalenc F, Rouanet P, Arnaud A, Arsene O, Ibrahim M, Wassermann J, Boileau-Jolimoy G, Martin A-L, Lemonnier J, André F, Arveux P (2019) Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. PLoS Med 16:e1002989. https://doi.org/10.1371/journal.pmed.1002989

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kichenadasse G, Miners JO, Mangoni AA, Rowland A, Hopkins AM, Sorich MJ (2020) Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. JAMA Oncol 6:512–518. https://doi.org/10.1001/jamaoncol.2019.5241

Article  PubMed  Google Scholar 

Kleinbongard P, Andreadou I (2024) Is there a mitochondrial protection via remote ischemic conditioning in settings of anticancer therapy cardiotoxicity? Curr Heart Fail Rep 21:292–304. https://doi.org/10.1007/s11897-024-00658-w

Article  PubMed  PubMed Central  Google Scholar 

Koene RJ, Prizment AE, Blaes A, Konety SH (2016) Shared risk factors in cardiovascular disease and cancer. Circulation 133:1104–1114. https://doi.org/10.1161/CIRCULATIONAHA.115.020406

Article  PubMed  PubMed Central  Google Scholar 

Korste S, Settelmeier S, Michel L, Odersky A, Stock P, Reyes F, Haj-Yehia E, Anker MS, Grüneboom A, Hendgen-Cotta UB, Rassaf T, Totzeck M (2023) Anthracycline therapy modifies immune checkpoint signaling in the heart. Int J Mol Sci 24:6052

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kucsera D, Ruppert M, Sayour NV, Tóth VE, Kovács T, Hegedűs ZI, Onódi Z, Fábián A, Kovács A, Radovits T, Merkely B, Pacher P, Ferdinandy P, Varga ZV (2024) NASH triggers cardiometabolic HFpEF in aging mice. GeroScience. https://doi.org/10.1007/s11357-024-01153-9

Article